It's out! Excited to share our latest work in Nat Comms.
We found that mutant Huntingtin impairs human neurodevelopment in brain organoid models through early disregulation of the mitochondrial protein CHCHD2.
Thanks to all coauthors!
https://t.co/az3UDiVzEK
Fruit flies that get #Alzheimer's @neuroprot: Flies with the disease barely crawl up the jars, or don't crawl up as fast.
Taufliegen, die Alzheimer bekommen: Fliegen mit der Erkrankung krabbeln in den Gläsern kaum noch oder nicht so schnell.
@LNDWBerlin@campusbuch#lndw24
Glad to share that our new, information-packed review is out: "Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects" https://t.co/fD4X1fR0pP
#Huntingtonsdisease#proteomics#PPIs#PolyQ
A new pipeline for prioritizing protein-protein interactions for #drugdiscovery, combining machine learning-based scoring of quantitative PPI data, protein complex structure prediction &virtual drug screening ➡️ https://t.co/ZEZ4L2NB6F @IMBA_Vienna@MDC_Berlin@harvardmed
My group @neuroprot is participating with an exciting project in auto-antibodies in neurodegenerative diseases. Check it out on the website, if you haven't already. Counting down till Sunday March 3rd.
Little over 2⃣ weeks left to submit your application for a fully-funded #PhDposition at #mdcBerlin! Join us for one of these topics: #genes, #cells & cell‑based medicine || molecular processes and therapies || integrative #biomedicine.
More: https://t.co/yzAHzt6Kux #mdcJobs#PhD
Researcher @andreaquezadaa is the Marie Skłodowska-Curie fellow at the #mdcBerlin. She works in the @neuroprot lab located on @campusbuch. Watch the video below 👇 to find out what exactly she investigates! #mdcVoices#mdcDiversity
Get even more details: https://t.co/WsH5cxji8N
“To develop new therapeutic approaches for #Huntington’s disease, we need a detailed understanding of the structure and composition of the fibrils”, says @andreaquezadaa. In the next 2 years she will create its atomic models @neuroprot.
#HuntingtonsDisease
https://t.co/WsH5cxji8N
Die aktuellen Antikörpertherapien sind die ersten neu zugelassenen Therapeutika für #Alzheimer seit 20 Jahren. Hoffentlich der Beginn eines starken Trends.